LRMR
Neutral signalScored 2026-08-03 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Larimar Therapeutics, Inc.
- Nom
- Larimar Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $244.1M
- Employés
- 71
- PDG
- Carole S. Ben-Maimon
- Site web
- https://www.larimartx.com
- Marché
- ACIUALTAMRNANNXANRODBVT
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 50000 titres (~166890 USD)
- Insiders
- Hamilton Thomas Edward
- Total bought
-
$166,890
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-07-06
- Last synced
-
2026-10-19 22:07:50
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-03 Drivers: fundamentals. Moteurs : fondamentaux.
LRMR presents a critically distressed financial profile with zero revenue, persistent operating losses, and negative cash flows, making the business model non-viable in its current state.
The first sentence of the analysis written for LRMR on 2026-08-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: fundamentals. Moteurs : fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 2.19 · operating margin 0.0%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 2.192 | 8.019 | 9.486 | 11.279 | 8.162 | |
| Quick Ratio | 2.192 | 8.019 | 9.486 | 11.279 | 8.162 | |
| Solvency Ratio | -2.440 | -2.826 | -2.577 | -2.260 | -3.530 | |
| Cash Ratio | 1.318 | 1.364 | 2.814 | 2.506 | 7.924 | |
| Price To Earnings Ratio | -1.678 | -2.932 | -5.417 | -3.105 | -3.683 | |
| Price To Earnings Growth Ratio | -0.023 | -0.051 | 0.147 | 0.057 | 0.208 | |
| Forward Price To Earnings Growth Ratio | -0.023 | -0.051 | 0.147 | 0.057 | 0.208 | |
| Price To Earnings Diluted Ratio | -1.678 | -2.932 | -5.417 | -3.105 | -3.683 | |
| Price To Earnings Diluted Growth Ratio | -0.023 | -0.051 | 0.147 | 0.057 | 0.208 | |
| Price To Book Ratio | 3.559 | 1.380 | 2.444 | 0.959 | 2.875 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -2.453 | -3.326 | -5.941 | -3.845 | -4.364 | |
| Price To Operating Cash Flow Ratio | -2.455 | -3.350 | -5.970 | -3.859 | -4.399 | |
| Debt To Assets Ratio | 0.028 | 0.026 | 0.058 | 0.043 | 0.076 | |
| Debt To Equity Ratio | 0.052 | 0.030 | 0.068 | 0.049 | 0.093 | |
| Debt To Capital Ratio | 0.050 | 0.029 | 0.064 | 0.046 | 0.085 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.868 | 1.165 | 1.174 | 1.140 | 1.221 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -1.747 | -2.905 | -3.520 | -2.575 | -4.760 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | 1.007 | 1.005 | 1.004 | 1.008 | |
| Debt Service Coverage Ratio | -149.614 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -102.444 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -27.834 | -13.828 | -6.033 | -5.098 | -7.015 | |
| Capital Expenditure Coverage Ratio | -1,243.967 | -137.398 | -204.020 | -275.690 | -126.441 | |
| Dividend Paid And Capex Coverage Ratio | -1,243.967 | -137.398 | -204.020 | -275.690 | -126.441 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -1.189 | -2.603 | -4.873 | -2.425 | -2.407 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 2.192 | ▼-5.827 | ▼-5.636 |
| Quick Ratio | 2.192 | ▼-5.827 | ▼-5.636 |
| Solvency Ratio | -2.440 | ▲0.386 | ▲0.287 |
| Cash Ratio | 1.318 | ▼-0.046 | ▼-1.867 |
| Price To Earnings Ratio | -1.678 | ▲1.253 | ▲1.685 |
| Price To Earnings Growth Ratio | -0.023 | ▲0.028 | ▼-0.091 |
| Forward Price To Earnings Growth Ratio | -0.023 | ▲0.028 | ▼-0.091 |
| Price To Earnings Diluted Ratio | -1.678 | ▲1.253 | ▲1.685 |
| Price To Earnings Diluted Growth Ratio | -0.023 | ▲0.028 | ▼-0.091 |
| Price To Book Ratio | 3.559 | ▲2.180 | ▲1.316 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -2.453 | ▲0.873 | ▲1.533 |
| Price To Operating Cash Flow Ratio | -2.455 | ▲0.895 | ▲1.551 |
| Debt To Assets Ratio | 0.028 | ▲0.002 | ▼-0.018 |
| Debt To Equity Ratio | 0.052 | ▲0.022 | ▼-0.006 |
| Debt To Capital Ratio | 0.050 | ▲0.021 | ▼-0.005 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.868 | ▲0.702 | ▲0.554 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -1.747 | ▲1.158 | ▲1.354 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | ▼-0.006 | ▼-0.004 |
| Debt Service Coverage Ratio | -149.614 | ▼-149.614 | ▼-119.691 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | -102.444 | ▼-102.444 | ▼-81.956 |
| Operating Cash Flow Coverage Ratio | -27.834 | ▼-14.006 | ▼-15.872 |
| Capital Expenditure Coverage Ratio | -1243.967 | ▼-1106.569 | ▼-846.464 |
| Dividend Paid And Capex Coverage Ratio | -1243.967 | ▼-1106.569 | ▼-846.464 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -1.189 | ▲1.414 | ▲1.510 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $277.9M | $237.1M | $199.8M | $106.4M | $185.2M | |
| Enterprise value | $196.6M | $209.0M | $178.5M | $85.0M | $121.1M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -1.74x | -2.95x | -5.34x | -3.08x | -2.88x | |
| EV / Free cash flow | -1.74x | -2.93x | -5.31x | -3.07x | -2.85x | |
| EV / EBITDA | -1.19x | -2.60x | -4.87x | -2.42x | -2.41x | |
| Net debt / EBITDA | 0.49x | 0.35x | 0.58x | 0.61x | 1.27x | |
| Current ratio | 2.19x | 8.02x | 9.49x | 11.28x | 8.16x | |
| Income quality | 0.68x | 0.88x | 0.91x | 0.78x | 0.83x | |
| Graham net-net | $1 | $3 | $2 | $4 | $3 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $77.2M | $170.9M | $80.7M | $110.0M | $63.4M | |
| Invested capital | $79.9M | $174.7M | $84.4M | $113.7M | $67.8M | |
| Return on assets | -113.6% | -40.3% | -38.5% | -28.0% | -64.4% | |
| Operating ROA | -99.7% | -61.4% | -37.6% | -35.6% | -55.0% | |
| Return on tangible assets | -113.6% | -40.3% | -38.5% | -28.0% | -64.4% | |
| Return on equity | -212.2% | -46.9% | -45.2% | -31.9% | -78.6% | |
| Return on invested capital | -210.0% | -51.4% | -47.9% | -31.4% | -71.7% | |
| Return on capital employed | -212.8% | -51.7% | -48.3% | -31.6% | -72.3% | |
| Earnings yield | -59.6% | -34.0% | -18.5% | -33.2% | -27.3% | |
| Free cash flow yield | -40.8% | -30.1% | -16.8% | -26.0% | -22.9% | |
| Capex / Op. cash flow | -0.1% | -0.7% | -0.5% | -0.4% | -0.8% | |
| Capex / Depreciation | 26.0% | 161.9% | 52.7% | 31.4% | 102.1% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+17.2%EV / Sales n/aEV / EBITDA ▲+54.3%EV / Op. cash flow ▲+1.216Earnings yield ▼-0.256
Profitability
Return on equity ▼-1.653Return on assets ▼-0.733Return on invested capital ▼-1.586Return on capital employed ▼-1.612Operating ROA ▼-0.383Income quality ▼-0.195Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-5.827Net debt / EBITDA ▲+0.142Working capital ▼-93721000.000Invested capital ▼-94749000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+50.1%EV / Sales n/aEV / EBITDA ▲+50.6%EV / Op. cash flow ▲+1.140Earnings yield ▼-0.323
Profitability
Return on equity ▼-1.336Return on assets ▼-0.492Return on invested capital ▼-1.383Return on capital employed ▼-1.406Operating ROA ▼-0.446Income quality ▼-0.148Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-5.970Net debt / EBITDA ▼-0.782Working capital ▲+13869000.000Invested capital ▲+12105000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Recent news
- 2026-10-10 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead Small-cap stocks tend to fly under the radar. Often in startup stages, these companies can lack analyst coverage, be overlooked by institutional investors, and be illiquid due to low average trading volume.
- 2026-10-05 Larimar (LRMR) Loses 22.7% in 4 Weeks, Here''s Why a Trend Reversal May be Around the Corner The heavy selling pressure might have exhausted for Larimar (LRMR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 2026-09-29 Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to Carole Ben-Maimon, M.D., Larimar''s Chief Executive Officer. Mr. Harlow joins Larimar with more than 25 years of commercial, operational and business development experience across the biopharmaceutical industry.
- 2026-09-14 5 Small Drug Stocks Poised to Benefit From a Biotech Recovery INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
- 2026-09-04 BlackRock Inc. Buys New Position in Larimar Therapeutics, Inc. $LRMR BlackRock Inc. purchased a new stake in Larimar Therapeutics, Inc. (NASDAQ: LRMR) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 5,678,035 shares of the company''s stock, valued at approximately $17,318,000. BlackRock Inc. owned 5.47% of Larimar Therapeutics as of its
- 2026-08-31 Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from Brokerages Shares of Larimar Therapeutics, Inc. (NASDAQ: LRMR - Get Free Report) have earned a consensus recommendation of "Buy" from the ten research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and three have issued a strong buy recommendation
- 2026-08-13 Dimensional Fund Advisors LP Purchases 470,968 Shares of Larimar Therapeutics, Inc. $LRMR Dimensional Fund Advisors LP lifted its position in shares of Larimar Therapeutics, Inc. (NASDAQ: LRMR) by 143.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 798,462 shares of the company''s stock after buying an additional 470,968 shares during
- 2026-08-04 Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update BALA CYNWYD, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its second quarter 2026 operating and financial results.
- 2026-07-23 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
- 2026-07-21 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Larimar Therapeutics, Inc. - LRMR NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.